Solid biosciences provides first quarter 2024 business update and financial results

— received rare pediatric disease and orphan drug designation for duchenne musculardystrophy (duchenne) gene therapy candidate sgt-003 with patient dosing in phase 1/2 trialexpected q2 2024 —

SLDB Ratings Summary

SLDB Quant Ranking